Moreover, this method could also serve as a platform to complement current staining and analysis methods for classification of HER2 breast cancer patients that are currently performed using IHC and in situ hybridization (ISH) scoring to distinguish HER2 positive and negative patients [65,66,67,68]. Here, ERBB2 is linked to breast carcinoma.